PI3K inhibitors are finally coming of age
Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
MA Occhiuzzi, G Lico, G Ioele, M De Luca… - European Journal of …, 2023 - Elsevier
The biochemical role of the PI3K/PKB/mTOR signalling pathway in cell-cycle regulation is
now well known. During the onset and development of different forms of cancer it becomes …
now well known. During the onset and development of different forms of cancer it becomes …
Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma
NH Fowler, F Samaniego, W Jurczak… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or
refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been …
refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been …
[HTML][HTML] Small molecule-based immunomodulators for cancer therapy
Y Wu, Z Yang, K Cheng, H Bi, J Chen - Acta Pharmaceutica Sinica B, 2022 - Elsevier
Immunotherapy has led to a paradigm shift in the treatment of cancer. Current cancer
immunotherapies are mostly antibody-based, thus possessing advantages in regard to …
immunotherapies are mostly antibody-based, thus possessing advantages in regard to …
Development and safety of PI3K inhibitors in cancer
M Yu, J Chen, Z Xu, B Yang, Q He, P Luo, H Yan… - Archives of …, 2023 - Springer
Abstract The phosphatidylinositol 3-kinase (PI3K) signalling pathway regulates cell survival,
proliferation, migration, metabolism and other vital cellular life processes. In addition …
proliferation, migration, metabolism and other vital cellular life processes. In addition …
Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies
G Li, Y Cheng, C Han, C Song, N Huang… - RSC Medicinal …, 2022 - pubs.rsc.org
Pyrazole is a five-membered heterocycle bearing two adjacent nitrogen atoms. Both
pharmaceutical agents and natural products with pyrazole as a nucleus have exhibited a …
pharmaceutical agents and natural products with pyrazole as a nucleus have exhibited a …
[HTML][HTML] Targeting the tumor microenvironment in chronic lymphocytic leukemia
R Svanberg, S Janum, PEM Patten, AG Ramsay… - …, 2021 - ncbi.nlm.nih.gov
The tumor microenvironment (TME) plays an essential role in the development, growth, and
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …
survival of the malignant B-cell clone in chronic lymphocytic leukemia (CLL). Within the …
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
M Tufail, JJ Hu, J Liang, CY He, WD Wan… - Journal of Translational …, 2024 - Springer
Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes
and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway …
and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway …
PI3K inhibitors for the treatment of chronic lymphocytic leukemia: current status and future perspectives
Simple Summary The development of small agents targeting the B-cell receptor (BCR)
pathway revolutionized the treatment of chronic lymphocytic leukemia (CLL). BCR …
pathway revolutionized the treatment of chronic lymphocytic leukemia (CLL). BCR …
Targeting casein kinase 1 (CK1) in hematological cancers
P Janovská, E Normant, H Miskin, V Bryja - International Journal of …, 2020 - mdpi.com
The casein kinase 1 enzymes (CK1) form a family of serine/threonine kinases with seven
CK1 isoforms identified in humans. The most important substrates of CK1 kinases are …
CK1 isoforms identified in humans. The most important substrates of CK1 kinases are …